FDA has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years and older who have moderate-to-severe atopic dermatitis (AD).

The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.

Adolescents were most likely to experience low energy/tiredness while children were most likely to report headache.

A recent review highlighted existing literature on the gut microbiome and type 2 diabetes and explored how focusing on the gut microbiome could assist with diabetes management.

Researchers found that brief bouts of anger can impair the ability of blood vessels to expand and contract, which might have consequences for heart health.

Breast cancer mortality was significantly lower among patients who used statins than in those who did not use these cholesterol-lowering drugs, a new study finds.

Kate Johnson DISCLOSURES | January 02, 2024

Six-month multidrug regimen being evaluated against standard treatment.

Findings highlight insufficient sleep as a modifiable risk factor for type 2 diabetes.